William Blair & Company’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$848K Sell
1,565
-35
-2% -$19.7K ﹤0.01% 1041
2026
Q1
$949K Sell
1,600
-200
-11% -$99.6K ﹤0.01% 962
2025
Q4
$877K Buy
1,800
+510
+40% +$238K ﹤0.01% 971
2025
Q3
$541K Sell
1,290
-53
-4% -$17.8K ﹤0.01% 1086
2025
Q2
$386K Buy
1,343
+243
+22% +$72.6K ﹤0.01% 1169
2025
Q1
$339K Sell
1,100
-32
-3% -$11K ﹤0.01% 1210
2024
Q4
$399K Buy
1,132
+6
+0.5% +$2.21K ﹤0.01% 1170
2024
Q3
$404K Sell
1,126
-1
-0.1% -$338 ﹤0.01% 1187
2024
Q2
$359K Sell
1,127
-435
-28% -$115K ﹤0.01% 1203
2024
Q1
$359K Buy
1,562
+29
+2% +$6.54K ﹤0.01% 1192
2023
Q4
$337K Buy
1,533
+17
+1% +$3.92K ﹤0.01% 1204
2023
Q3
$342K Buy
1,516
+16
+1% +$3.69K ﹤0.01% 1176
2023
Q2
$331K Buy
+1,500
New +$332K ﹤0.01% 1211
2022
Q1
– Sell
-3,053
Closed -$660K – 2014
2021
Q4
$660K Buy
+3,053
New +$599K ﹤0.01% 1108
2014
Q4
– Sell
-1,600
Closed -$206K – 2150
2014
Q3
$206K Buy
+1,600
New +$165K ﹤0.01% 1964

Other funds holding UTHR

William Blair & Company's UTHR Position: Q2 2026 in Review

William Blair & Company reduced its United Therapeutics (UTHR) stake by 2.2% in Q2 2026, selling an estimated $19.7K and leaving 1,565 shares worth $848K. The position accounts for ﹤0.01% of the portfolio, ranked #1041.

William Blair & Company first reported a position in UTHR in Q3 2014 and has held it in 15 quarters since. The position peaked at $949K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • William Blair & Company held 1,565 shares of United Therapeutics worth $848K as of Q2 2026.
  • William Blair & Company sold 35 United Therapeutics shares in Q2 2026, an estimated $19.7K.
  • United Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1041 holding.
  • William Blair & Company first reported a position in United Therapeutics in Q3 2014 and has held it in 15 quarters since.
  • William Blair & Company's United Therapeutics position peaked at $949K in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.